Delivery Hero, the German food delivery service, has raised $110 million from two undisclosed U.S. investors. The latest funding round values the company at $3.1 billion. Previous investors in Delivery Hero include Insight Venture Partners, General Atlantic and Rocket Internet. The company, which is active in 34 countries, will use the latest funds for acquisitions and new products.
Menlo Securities has launched from stealth, unveiling its malware protection platform and $25 million in Series B funding. Sutter Hill Ventures led the round, and was joined by previous backers General Catalyst, Osage University Partners and Engineering Capital. “What Menlo Security is doing with isolation is revolutionary for the security industry and unprecedented for organizations in search of tangible, effective threat prevention,” David Giambruno, senior vice president and chief information officer of Tribune Media said in a press release. “While detection solutions can’t prevent modern malware, and early isolation solutions are too hindering to the end user, Menlo Security has ‘cracked the code’ and found a way to preserve user experience while exponentially reducing risk and enabling the security and IT teams to change operating paradigms.”
Jimdo, a DIY website builder, has raised $28 million from Spectrum Equity. The company’s service is available in eight languages, with offices in Hamburg, Tokyo and San Francisco. “We’re incredibly proud of having built Jimdo with only €500,000 of outside capital,” said Matthias Henze, co-founder of Jimdo, “But now it is time to take Jimdo to the next level and pursue the additional product and market opportunities that are available to the company in this rapidly growing market. For this step, we are really happy that we have found the right partner in Spectrum—they have a deep understanding of our business, and have a long term perspective, just like we do.”
Celtaxsys, which is developing therapies for inflammatory diseases, has raised $40 million in Series D financing led by Domain Partners VIII. Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund. The Cystic Fibrosis Foundation Therapeutics Foundation supplemented the financing with a $5 million grant. “The proceeds from this financing, led by top-tier biotechnology investors, speaks to the investment community’s support for developing innovative anti-inflammatory medicines for patients diagnosed with orphan diseases. We believe CTX-4430’s ability to reduce neutrophil elastase in the airways of CF patients has the potential to preserve lung function in CF patients, irrespective of patient-specific CF gene mutation,” said Greg Duncan, President and CEO of Celtaxsys.